DAYVIGO

This brand name is authorized in United States. It is also authorized in Canada, Hong Kong SAR China, Israel, Japan.

Active ingredients

The drug DAYVIGO contains one active pharmaceutical ingredient (API):

1	Lemborexant UNII 0K5743G68X - LEMBOREXANT
	Lemborexant is an orexin receptor antagonist. The orexin neuropeptide signaling system plays a role in wakefulness. Blocking the binding of wake-promoting neuropeptides orexin A and orexin B to receptors OX1R and OX2R is thought to suppress wake drive.

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
DAYVIGO Film-coated tablet	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
N05CM	Other hypnotics and sedatives	N Nervous system → N05 Psycholeptics → N05C Hypnotics and sedatives
Discover more medicines within N05CM

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
CA	Health Products and Food Branch	02507366, 02507374
HK	Department of Health Drug Office	67001, 67002
IL	מִשְׂרַד הַבְּרִיאוּת	9411, 9412
JP	医薬品医療機器総合機構	1190027F1022, 1190027F2029, 1190027F3025
US	FDA, National Drug Code	62856-405, 62856-410, 62856-455